Newsfeeds - Spark Newswire

2 minute read

Biohaven Provides Update On Phase 3 Clinical Trial Evaluating Troriluzole For Spinocerebellar Ataxia; Co. Reports The Primary Endpoint Did Not Reach Statistical Significance In The Overall SCA Population

Today, 2:44 PM

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of its investigational therapy, troriluzole, in patients with

BHVN

3 minute read

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More

By Shanthi Rexaline

Today, 2:44 PM

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.

ATNX

1 minute read

Morgan Stanley Maintains Equal-Weight on Biohaven Pharma Hldgs, Raises Price Target to $148.5

By Benzinga Newsdesk

Today, 2:44 PM

Morgan Stanley maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Equal-Weight and raises the price target from $146 to $148.5.

BHVN

7 minute read

103 Biggest Movers From Yesterday

By Lisa Levin

Today, 2:44 PM

Gainers

AFI

1 minute read

SVB Leerink Downgrades Biohaven Pharma Hldgs to Market Perform

By Benzinga Newsdesk

Today, 2:44 PM

SVB Leerink analyst Marc Goodman downgrades Biohaven Pharma Hldgs (NYSE:BHVN) from Outperform to Market Perform.

BHVN

5 minute read

77 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 2:44 PM

Gainers

AFRM

3 minute read

Mid-Morning Market Update: Markets Open Higher; Nasdaq Jumps Over 200 Points

By Lisa Levin

Today, 2:44 PM

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 200 points on Tuesday.

AHCO

1 minute read

Recap: Biohaven Pharma Hldgs Q1 Earnings

By Benzinga Insights

Today, 2:44 PM

Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:50 AM. Here's what investors need to know about the announcement.

BHVN

4 minute read

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

By Vandana Singh

Today, 2:44 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ACHV

2 minute read

Pfizer and Biohaven’s VYDURA Granted First Ever Marketing Authorization By European Commission For Both Acute Treatment Of Migraine And Prophylaxis Of Episodic Migraine

By Benzinga Newsdesk

Today, 2:44 PM

Pfizer Inc. (NYSE:PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant), a calcitonin

BHVN